Health Catalyst, Inc. (NASDAQ:HCAT) Stock Position Decreased by Inspire Investing LLC

Inspire Investing LLC trimmed its stake in Health Catalyst, Inc. (NASDAQ:HCAT) by 10.1% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 49,360 shares of the company’s stock after selling 5,574 shares during the quarter. Inspire Investing LLC owned approximately 0.08% of Health Catalyst worth $402,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Nisa Investment Advisors LLC increased its stake in Health Catalyst by 461.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock worth $41,000 after purchasing an additional 5,232 shares in the last quarter. Quarry LP increased its position in shares of Health Catalyst by 59.4% in the second quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after acquiring an additional 2,610 shares in the last quarter. Perfromance Wealth Partners LLC acquired a new stake in shares of Health Catalyst during the second quarter valued at approximately $64,000. Mackenzie Financial Corp purchased a new stake in shares of Health Catalyst in the 2nd quarter valued at approximately $70,000. Finally, EntryPoint Capital LLC acquired a new position in Health Catalyst in the 1st quarter worth approximately $98,000. 85.00% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Evercore ISI increased their target price on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. JPMorgan Chase & Co. raised their price objective on Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 4th. Stephens dropped their target price on Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating on the stock in a report on Thursday, August 8th. Cantor Fitzgerald restated an “overweight” rating and set a $16.00 price target on shares of Health Catalyst in a report on Friday, October 4th. Finally, Piper Sandler lowered their price objective on shares of Health Catalyst from $14.00 to $11.00 and set an “overweight” rating on the stock in a research report on Monday, August 26th. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.58.

Insider Activity

In related news, COO Daniel Lesueur sold 8,137 shares of the business’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total value of $61,678.46. Following the completion of the sale, the chief operating officer now directly owns 140,108 shares in the company, valued at approximately $1,062,018.64. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Health Catalyst news, COO Daniel Lesueur sold 8,137 shares of the stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total transaction of $61,678.46. Following the transaction, the chief operating officer now owns 140,108 shares in the company, valued at $1,062,018.64. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Kevin Lee Freeman sold 7,500 shares of the business’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the sale, the insider now owns 255,881 shares of the company’s stock, valued at $1,847,460.82. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 35,396 shares of company stock valued at $258,415. Insiders own 2.70% of the company’s stock.

Health Catalyst Stock Up 0.1 %

Shares of HCAT opened at $8.66 on Friday. The firm has a market cap of $511.24 million, a price-to-earnings ratio of -4.68 and a beta of 1.32. The company’s fifty day moving average is $7.71 and its 200-day moving average is $6.94. Health Catalyst, Inc. has a 12 month low of $5.42 and a 12 month high of $11.41.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.04. Health Catalyst had a negative net margin of 28.87% and a negative return on equity of 9.38%. The firm had revenue of $75.90 million during the quarter, compared to analysts’ expectations of $74.96 million. During the same period in the prior year, the company posted ($0.21) earnings per share. Health Catalyst’s revenue for the quarter was up 3.7% on a year-over-year basis. As a group, research analysts predict that Health Catalyst, Inc. will post -0.35 earnings per share for the current fiscal year.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.